Bibliometric Study on Sorafenib in Liver Cancer
Author Information
Author(s): Meng Wenjun, Luo Yihang, Zhao Lu, Zhang Yaoyu, Liu Jiyan, Li Shadan, Du Yang, Li Hongshuai
Primary Institution: West China Hospital, Sichuan University
Hypothesis
No detailed scientometric examination of sorafenib's knowledge framework in hepatocellular carcinoma has been undertaken.
Conclusion
The bibliometric analysis identified current hotspots and trends in the sorafenib-HCC field, providing guidance for future research.
Supporting Evidence
- 7,667 articles related to sorafenib in HCC were retrieved from the WoSCC database.
- China published the most papers, accounting for 50.66% of the total volume.
- The journal 'Cancers' had the most papers published in this field.
- Masatoshi Kudo published the most research papers among authors.
- Current research hotspots include 'survival', 'apoptosis', and 'efficacy'.
Takeaway
This study looked at many articles about a medicine called sorafenib used for liver cancer, helping researchers see what topics are popular and where more studies are needed.
Methodology
VOSviewer and CiteSpace were used to analyze articles from the Web of Science Core Collection database.
Potential Biases
Potential biases due to changes in author and institution names.
Limitations
Only one database was used, potentially missing relevant publications; non-English publications were excluded.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website